These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 16495253

  • 1. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
    [Abstract] [Full Text] [Related]

  • 2. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE, COL104422 Study Team.
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [Abstract] [Full Text] [Related]

  • 3. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA, COL10053 Study Team.
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [Abstract] [Full Text] [Related]

  • 4. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW.
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M, Clay PG, Anderson PL, Glaros AG.
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [Abstract] [Full Text] [Related]

  • 7. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba AD.
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
    [Abstract] [Full Text] [Related]

  • 10. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
    DeJesus E, Piliero PJ, Summers K, Wire MB, Stein DS, Masterman A, Lou Y, Min SS, Shelton MJ.
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3157-9. PubMed ID: 16940117
    [Abstract] [Full Text] [Related]

  • 11. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
    Busti AJ, Bain AM, Hall RG, Bedimo RG, Leff RD, Meek C, Mehvar R.
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 13. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1578-80. PubMed ID: 16569890
    [Abstract] [Full Text] [Related]

  • 14. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 15. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C, Smith P, Morrison R, Riek M, Patel A, Schmitt C, Morcos PN, Zhang X.
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [Abstract] [Full Text] [Related]

  • 16. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I.
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
    Cotton M, Cassim H, Pavía-Ruz N, Garges HP, Perger T, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Sievers J, Cheng K.
    Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
    [Abstract] [Full Text] [Related]

  • 18. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
    Reddy YS, Ford SL, Anderson MT, Murray SC, Ng-Cashin J, Johnson MA.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1202-8. PubMed ID: 17261626
    [Abstract] [Full Text] [Related]

  • 19. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 Apr; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 20. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.
    Ford SL, Wire MB, Lou Y, Baker KL, Stein DS.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):467-9. PubMed ID: 15616339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.